Novo Nordisk A/S NVO
Novo Nordisk A/S (NYSE: NVO) is a cardio-renal-metabolic drug developer. Its lead program, Semaglutide franchise (Ozempic, Wegovy, Rybelsus) and GLP-1/insulin portfolio, is in Phase 3 for Type 2 diabetes and obesity. Its next catalyst on record is Ozempic® pill (25 mg): US decision expected for Ozempic® pill 25 mg in Q4 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Ozempic® pill (25 mg) — US decision expected for Ozempic® pill 25 mg in Q4 2026. (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Ozempic / Rybelsus (semaglutide) | Type 2 diabetes | protein/peptide | Approved |
| Wegovy (injectable and oral Wegovy Pill) / Saxenda | Obesity | protein/peptide | Approved |
| Insulin portfolio (Tresiba, NovoLog/NovoRapid, Fiasp, Levemir, Xultophy) | Diabetes | protein/peptide | Approved |
| Rare disease (Norditropin growth hormone, NovoSeven haemophilia) | Growth disorders, haemophilia | protein/peptide | Approved |
| Efruxifermin (EFX), acquired with Akero Therapeutics December 2025 | MASH (metabolic dysfunction-associated steatohepatitis) | protein/peptide | Phase 3 |
Recent results and decisions
- Nov 4, 2026positive CagriSema delivered 21% weight loss at week 68 in REDEFINE 9 trial.
Within obesity, CagriSema (1.0/1.0 mg) delivered encouraging weight loss of 21% at week 68 in the REDEFINE 9 trial.
Filing - Nov 4, 2026submitted Novo submitted to US FDA for paediatric label update for Ozempic® based on PIONEER TEENS trial.
Regulatory submission was made to the US Food and Drug Administration (FDA) for a paediatric label update for Ozempic®, the submission was based on data from the PIONEER TEENS trial.
Filing - Nov 4, 2026submitted Novo submitted paediatric label update for Rybelsus® to EMA and Ozempic® pill to FDA based on PIONEER TEENS data.
Regulatory submissions were made to the EU European Medicines Agency (EMA) and to the US Food and Drug Administration (FDA) for a paediatric label update for Rybelsus® and Ozempic® pill, the submission was based on data from the PIONEER TEENS trial.
Filing
43 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.